GlassScriptPhysician profile
Matthew F Alvarez
NPI 1013022946
$1,245.92
in general payments reported to CMS, 2019-2025
21 companies · $271 in 2025
The $271 reported for 2025 was more than what a typical Obstetrics & Gynecology provider received nationally (typical 2025 total: $158).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $171 · 2020: $52.12 · 2022: $18.62 · 2023: $53.88 · 2024: $679 · 2025: $271.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Honoraria: $550 · Food and Beverage: $454.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Honoraria | $550.00 |
| Food and Beverage | $454.31 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Becton, Dickinson and Company | $550.00 | 2024 | |
| Bayer Healthcare Pharmaceuticals INC. | $150.56 | 2019-2025 | |
| Coopersurgical, INC. | $78.19 | 2024-2025 | Paragard T 380a, Endosee |
| Pfizer INC. | $67.55 | 2019-2025 | |
| Astellas Pharma US INC | $60.18 | 2024-2025 | Veozah |
| Vertical Pharmaceuticals, LLC | $36.71 | 2019 | |
| Merck Sharp & Dohme LLC | $35.26 | 2019 | |
| Exeltis, USA INC. | $34.40 | 2025 | Slynd |
| Biogen, INC. | $27.98 | 2025 | Zurzuvae |
| Sumitomo Pharma America, INC. | $26.82 | 2025 | Myfembree |
| Amag Pharmaceuticals, INC. | $25.57 | 2019-2020 | |
| Mylan Pharmaceuticals INC. | $24.29 | 2019 | |
| Vertex Pharmaceuticals Incorporated | $21.31 | 2025 | |
| Novo Nordisk INC | $18.93 | 2023 | Wegovy |
| Evofem Biosciences, INC. | $18.80 | 2024 |
Show all 20 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $15.46 | 2019 | |
| Hologic Sales and Service, LLC | $15.06 | 2024 | Myosure Tissue Removal Device, Acessa Provu System |
| Millicent US INC | $13.57 | 2025 | Femlyv |
| Duchesnay USA Incorporated | $12.94 | 2019 | |
| Therapeuticsmd, INC. | $12.34 | 2019 |
1 company reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
Research and ownership
$5.00 in ownership or investment interests, as reported to CMS. These are holdings a clinician or an immediate family member has in a company, not payments received.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Matthew Alvarez listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.